Gyre Therapeutics Appoints Three New Members to its Board of Directors
SAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. ("Gyre”, "Gyre Therapeutics” or the "Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with…
Read the full articleYou might also wanna read
On the Move: Ovid Therapeutics Hires Fort as CSO
Ovid Therapeutics names Victoria Fort, a veteran of GCI Health, Ruder Finn and Chandler Chicco, as chief strategy officer and chief of staff
Viking Therapeutics Aktie: 41 Prozent Plus in 30 Tagen
Viking Therapeutics steht vor einer entscheidenden Phase. Die Aktie korrigiert heute deutlich, nachdem sie erst am Dienstag ein neues 52-Woc
Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up
A Phase 3 trial failure has erased a year of gains for Ionis Pharmaceuticals in just days, and the ripple effects are rattling rivals across
AI accelerates search for cancer therapeutics in Korea
Artificial intelligence (AI) has helped SK Telecom and SK Biopharmaceuticals identify promising early compounds for a targeted cancer therap
디앤디파마텍, 美 화이자 비만 치료제 연구 용역 계약 확대
바이오 기업 디앤디파마텍은 미국 제약사 화이자(Pfizer)와 체결한 경구용 펩타이드 비만치료제 제형 개발 관련 연구용역 계약 규모가 확대됐다고 14일 공시했다. 회사는 해당 계약 금액이 기존 18억3266만원에서 25억2657만원으로 변경됐다고 정정
Upcoming 2026 FDA Decisions Could Expand Treatment Options Across Oncology and Hepatitis B
Accessed July 7, 2026. 7. Ionis’ partner GSK announces bepirovirsen accepted for priority review and granted breakthrough therapy designatio
Comments
Sign in to join the conversation.
No comments yet. Be the first.